In a significant boost to its growth plans, ELMED Life Sciences has raised $2.7 million (₹25 crore) in Series A funding from AgriSURE Fund, managed by NABVENTURES. The investment will support expansion in manufacturing, R&D and market reach.
Founded by Pruthivin Reddy Madduri and co-founded by Nikhil Konkathi, the company focuses on probiotic and biological solutions across animal health, agriculture, aquaculture and human health. Its offerings are tailored for poultry, dairy, livestock, shrimp, fish farming and soil health.
The funding comes as agriculture shifts towards microbiome-based and biological solutions. This change is driven by stricter regulations on antibiotics, higher export standards for residue-free produce and growing awareness around sustainable farming. In India, adoption is rising across poultry, dairy and aquaculture sectors.
ELMED plans to expand its manufacturing facility in Hyderabad and strengthen its research in microbiome-based innovation. It will also scale its distribution network across Tier 2 and Tier 3 markets while expanding globally to meet demand for sustainable and antibiotic-free solutions.
“We founded ELMED Life Sciences with one conviction that nature’s own biological intelligence, when harnessed through rigorous science, can transform the health and productivity of animals, humans, aquatic systems, and soil. The support of the AgriSURE Fund is a strategic partnership with an institution that understands this market from the ground up. With this funding, we are ready to take ELMED to its next chapter: deeper into the heart of Indian agriculture, and broader into global markets that increasingly demand clean, biological, and residue-free solutions. The opportunity ahead of us is immense, and we are only getting started.” Pruthivin Reddy Madduri, Founder & Managing Director, ELMED Life Sciences
Speaking on the investment, Ashish Choudhary, Investment Manager at AgriSURE Fund, NABVENTURES, said, “Indian agriculture is steadily moving towards more sustainable and residue-free practices, creating a strong need for reliable biological solutions. Through the AgriSURE Fund, we focus on backing businesses that can drive this shift at scale. ELMED has demonstrated both scientific strength and on-ground adoption across key agri segments, and this investment will support its next phase of growth in manufacturing and market expansion.”
“ELMED operates in a rapidly emerging segment within the probiotic and biological solutions space, with strong growth potential. The company’s positioning and scalability make it a compelling opportunity. We are pleased to have supported this funding.” said Sumeet Seraf.
Currently headquartered in Hyderabad, ELMED operates across India and serves multiple MNCs through a B2B model. The company exports to over 18 countries and plans to expand further across Europe, Asia and South America. It is also the first company in India to develop probiotics specifically for agriculture.
Looking ahead, ELMED aims to scale operations across domestic and global markets while continuing to invest in science-led innovation focused on the ONE HEALTH approach.
Also read: Viksit Workforce for a Viksit Bharat
Do Follow: The Mainstream LinkedIn | The Mainstream Facebook | The Mainstream Youtube | The Mainstream Twitter
About us:
The Mainstream is a premier platform delivering the latest updates and informed perspectives across the technology business and cyber landscape. Built on research-driven, thought leadership and original intellectual property, The Mainstream also curates summits & conferences that convene decision makers to explore how technology reshapes industries and leadership. With a growing presence in India and globally across the Middle East, Africa, ASEAN, the USA, the UK and Australia, The Mainstream carries a vision to bring the latest happenings and insights to 8.2 billion people and to place technology at the centre of conversation for leaders navigating the future.
